Optimization of amoxicillin/clavulanate therapy based on pharmacokinetic/pharmacodynamic parameters in diabetic foot infection patients;Optimalizace léčby amoxicilín/klavulanátem na základě PK/PD parametrů u nemocných s infekcí při syndromu diabetické nohy

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 10, Issue 4, 2004, Pages 167-175

  Šedivý, Josef ^a   Petkov, V ^a   Jirkovska A ^a   Stambergova A ^a   Ulbrichova Z ^a   Lupinkova J ^a   Fejfarova V ^a   Bem R ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Amoxicillin clavulanate; Dosing regimen optimization; Growth killing rates

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CELL VIABILITY; CLINICAL PROTOCOL; DIABETIC FOOT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; HUMAN; IN VITRO STUDY; INFECTION; MICROBIAL ACTIVITY; OSCILLATION; PHARMACODYNAMICS; PREDICTION; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; STEADY STATE; DRUG COMBINATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; STAPHYLOCOCCUS INFECTION;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; DIABETIC FOOT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 4644221311     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wagner FW Jr. Treatment of the diabetic foot. Compr Ther 1984;10:29-38.
2. Lipsky BA Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immun Med Microbiol 1999;26:267-276.
3. Kalani M, Brismar K, Fagrell B, et al. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999;22:147-151.
4. Proost JH, Meijer DF. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;27:155-163.
5. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokineric equations. J Pharmacokin Biopharm 1978;6:165-175.
6. Janků I. Kvantitativní zákonitosti pohybu léčiv v organismu. In: Farmakokinetic-ké zá klady dávkování léků. Ed.: Janků I, Avicenum, Praha 1986:29.
7. Wagner JG: Noncompartmental and system analysis. In: Pharmacokinetics for the pharmaceutical scientist. Ed.: Wagner JG, Technomic Publ.Co., Lancaster Basel, 1993,83-102.
8. Sauter R, Steinijans VW, Diletti E, et al. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Tox 1992;30(Suppl 1):7-30.
9. Urbášková P. Rezistence bakterií k antibiotikům - vybrané metody. Kapitola 3. Trios, Praha, 1998.
10. Zhi J, Nightingale CH, Quintiliani R. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci 1986;75:1063-1067.
11. Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11:229-239.
12. Mouton JW, Vinks AATMM, Punt NC: Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997;41:733-738.
13. Neef C, vanGils SA, IJzermar WL: Analogy between temperature-dependent and concentration-dependent bacterial killing. Comput Biol Med 2002;32:529-549.
14. Anděl J: Matematická statistika. SNTL/ALFA, Praha, 1985,232.
15. Brogden RN, Carmine A, Heel RC, et al. Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs 1981; 22:337-362.
16. Boselli E, Allaouchiche B. Diffusion in bone tissue of antibiotics. Presse Med 1999;28:2265-2276.
17. Šedivý J. Terapeutické monitorování léčiv. Postgrad Med 2002;4:318-323.
18. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995;14:636-642.
19. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
20. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother 1994;38:2730-2737.
21. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determination. Antimicrob Agents Chemother 1998;42:2375-2379.
22. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-936.
23. Craig WA, Ebert SC. Minireview: Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-2583.